Managing Cancer and Living Meaningfully (CALM): Phase 2b Pilot Randomized Psychotherapy Trial in Patients With Advanced Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- University Health Network, Toronto
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Patient Health Questionnaire-9 (PHQ-9)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Managing Cancer And Living Meaningfully (CALM) is a brief psychotherapy designed to alleviate distress in advanced cancer. In an earlier intervention-only pilot trial, CALM was associated with reductions in depressive symptoms and death anxiety and an increase in spiritual wellbeing. The purpose of this study is to assess the feasibility of a large-scale randomized controlled trial (RCT) of CALM and to identify preliminary effects in advanced cancer. This phase 2b pilot RCT employed intervention and usual care arms with 3 and 6 month follow-ups. The primary outcome was depressive symptoms (PHQ-9) and secondary outcomes included diagnosis of major depression (SCID), death anxiety, attachment security and spiritual wellbeing. Multilevel regression was used to compare change over time between groups. 60 patients with advanced cancer will be recruited from the Princess Margaret Cancer Centre, Toronto, Canada, and equally randomized into intervention and usual care conditions.
Detailed Description
Abstract Background Managing Cancer And Living Meaningfully (CALM) is a brief individual psychotherapy for patients with advanced cancer. In an intervention-only phase 2a trial, CALM showed promising results, leading to the present 2b pilot, which introduces procedures for randomisation and improved rigour in preparation for a phase 3 randomised controlled trial (RCT). Aims To test trial methodology and assess feasibility of a confirmatory RCT. Design A parallel-arm RCT (intervention vs usual care) with 3 and 6-month follow-ups. Assessment of feasibility included rates of consent, randomisation, attrition, intervention non-compliance and usual care contamination. Primary outcome: depressive symptoms (Patient Health Questionnaire-9; PHQ-9). Secondary outcomes: major depressive disorder (MDD), generalised anxiety, death anxiety, spiritual well-being, attachment anxiety and avoidance, self-esteem, experiential avoidance, quality of life and post-traumatic growth. Bayesian conjugate analysis was used in this low-powered setting. Setting/participants 60 adult patients with advanced cancer from the Princess Margaret Cancer Centre. Trial registration number NCT02353546. http://dx.doi.org/10.1136/bmjspcare-2015-000866
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •Fluent in English
- •Confirmed diagnosis of Stage IIIB or IV lung cancer, Stage III or IV ovarian cancer, Stage IV endocrine, breast, gastrointestinal, genitourinary or gynecologic cancer, or pancreatic cancer at any stage
Exclusion Criteria
- •Short Orientation-Memory-Concentration Test (score of \<20)
- •Individuals receiving in-hospital psychiatric or psychological treatment at the time of recruitment
Outcomes
Primary Outcomes
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: 6-months
Secondary Outcomes
- Generalized Anxiety Disorder-7 (GAD-7)(6-months)
- Functional Assessment of Chronic Illness Therapy-Spiritual Well-being Scale (FACIT-Sp-12)(6-months)
- Acceptance and Action Questionnaire-II (AAQ-II)(6-months)
- Death and Dying Distress Scale (DADDS)(6-months)
- Quality of Life at the End of Life-Cancer Scale (QUAL-EC)(6-months)
- Major Depression Structured Clinical Interview for DSM Disorders (SCID)(6-months)
- Posttraumatic Growth Inventory (PTGI)(6-months)
- Modified Experiences in Close Relationships (ECR M-16)(6-months)
- Rosenberg Self-esteem Scale (RSES)(6-months)